Urothelial Carcinoma
1Department of Pathology, College of Medicine, National Cheng Kung University, No. 1 University Road, Tainan 701, Taiwan
2Section of Experimental Oncology, Cancer Research UK Clinical Centre, Leeds Institute for Molecular Medicine, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK
3The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, 600 N. Wolfe Street, Marburg 409, Baltimore, MD 21287, USA
Urothelial Carcinoma
Description
Bladder cancer is a common urologic cancer. In North America, South America, Europe, and Asia, the most common type of epithelial tumor diagnosed is urothelial (transitional cell) carcinoma. Worldwide, however, squamous cell carcinoma (SCC) is the most common form of bladder cancer, accounting for 75% of cases in developing nations. Urothelial carcinoma of the bladder is intriguing to both biologists and oncologists. Clinical management of this type of bladder cancer is challenging for its heterogeneity among bladder tumors with respect to invasion and metastasis, and frequent recurrence in the bladder among patients treated with bladder preservation therapies. The dilemma of clinical practice has stimulated the translational research. At the same time, the characteristics of environment-driven carcinogenesis and divergent molecular pathways in the development of low- and high-grade tumors provide a unique opportunity for molecular research in cancer biology. Bladder cancer is also at the forefront of biomarker development because of the ease of developing noninvasive urine tests. The objective of this special issue is to present both reviews of translational research in the bladder cancer and up-to-date summaries related to molecular pathogenesis, diagnosis, prognostic assessment, and management of bladder cancer. It is hoped that this volume can bring the latest information to all urologists, pathologists, and medical oncologists who wish to provide their patients with the most comprehensive care.
We invite investigators to contribute original work, as well as review articles, for all aspects of bladder cancer research. We are particularly interested in articles describing the latest discoveries of tumor biology, cancer genetics, molecular epidemiology, novel therapeutics, and cancer prevention. The final goal of this issue is to stimulate the development of early detection, prevention, and treatment for human bladder cancer. Potential topics include, but are not limited to:
- Recent developments of basic science research in urothelial bladder cancer
- Advances in genetics of bladder cancer
- Latest technologies for molecular diagnosis of bladder cancer
- Role of molecular biomarkers in clinical evaluation and measuring outcomes
- Recent progress in clinical management of patients with muscle-invasive bladder cancer, including urinary diversion and laparoscopic cystectomy
- Recent progress in the prevention of urothelial carcinogenesis
- Recent advances in epidemiology of urothelial bladder cancer
- Advances in the development of targeted therapy for bladder cancer
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/au/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: